Analiza učinka mRNA BNT162b cjepiva na angiogene čimbenike PlGF i sFlt-1

Matić, Tamara

prikaz prve stranice dokumenta Analiza učinka mRNA BNT162b cjepiva na angiogene čimbenike PlGF i sFlt-1

Embargo period 2025-06-27

master's thesis

Analiza učinka mRNA BNT162b cjepiva na angiogene čimbenike PlGF i sFlt-1

Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry, 2023. urn:nbn:hr:163:579138

Matić, Tamara

University of Zagreb
Faculty of Pharmacy and Biochemistry
Department of medical biochemistry and haematology

Cite this document

APA 6th Edition

Matić, T. (2023). Analiza učinka mRNA BNT162b cjepiva na angiogene čimbenike PlGF i sFlt-1 (Master's thesis). Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:579138

MLA 8th Edition

Matić, Tamara. "Analiza učinka mRNA BNT162b cjepiva na angiogene čimbenike PlGF i sFlt-1." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2023. https://urn.nsk.hr/urn:nbn:hr:163:579138

Chicago 17th Edition

Harvard

Matić, T. (2023). 'Analiza učinka mRNA BNT162b cjepiva na angiogene čimbenike PlGF i sFlt-1', Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, accessed 26 January 2025, https://urn.nsk.hr/urn:nbn:hr:163:579138

Vancouver

Matić T. Analiza učinka mRNA BNT162b cjepiva na angiogene čimbenike PlGF i sFlt-1 [Master's thesis]. Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry; 2023 [cited 2025 January 26] Available at: https://urn.nsk.hr/urn:nbn:hr:163:579138

IEEE

T. Matić, "Analiza učinka mRNA BNT162b cjepiva na angiogene čimbenike PlGF i sFlt-1", Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, 2023. Available at: https://urn.nsk.hr/urn:nbn:hr:163:579138

Cite this item: https://urn.nsk.hr/urn:nbn:hr:163:579138

Please login to the repository to save this object to your list.

Metadata

Title	Analiza učinka mRNA BNT162b cjepiva na angiogene čimbenike PlGF i sFlt-1
Title (english)	Analysis of mRNA BNT162B vaccine effect on angiogenic factors PlGF and sFlt-1
Author	Tamara Matić
Mentor	Anita Somborac Bačura (mentor)
Mentor	Domagoj Marijančević (mentor)
Committee member	Anita Somborac Bačura (predsjednik povjerenstva)
Committee member	Sandra Šupraha-Goreta (član povjerenstva)
Committee member	Domagoj Marijančević (član povjerenstva)
Granter	University of Zagreb Faculty of Pharmacy and Biochemistry (Department of medical biochemistry and haematology) Zagreb
Defense date and country	2023-06-27, Croatia
Scientific / art field, discipline and subdiscipline	BIOMEDICINE AND HEALTHCARE Pharmacy Medical Biochemistry
Abstract	Pojava tromboembolijskih incidenata s početkom procjepljivanja protiv SARS-CoV-2 zasigurno je jedna od najvećih dilema koju je donijela pandemija Covid-19. Vodeći se činjenicom da cijepljenje oponaša prirodnu infekciju, pretpostavljeno je da uslijed poremećene regulacije renin-angiotenzin sustava vezanjem šiljastog proteina može doći do angiogene neravnoteže te hiperkolagulabilnog stanja koje je u pozadini tromboemboliskih incidenata. U skladu s tim, ovim istraživanjem ispitivan je učinak mRNA BNT162b cjepiva na koncentracije angiogenih čimbenika PlGF i sFlt-1. Konkretni ciljevi bili su ispitati utjecaj cijepljenja na koncentracije PlGF i sFlt-1, razliku u koncentracijama između podskupina ispitanika bez hipertenzije i s hipertenzijom, te povezanost PlGF i sFlt-1 s dobi te indeksom tjelesne mase u pojedinim vremenskim točkama nakon cijepljenja. Predmet ovog istraživanja bila su 33 odrasla ispitanika cijepljena mRNA BNT162b cjepivom. Koncentracije čimbenika mjerene su istovjetno u 5 vremenskih točaka: T0 – točka mjerenja neposredno prije 1. doze (unutar 24h); T1 – točka mjerenja 7 dana nakon 1. doze; T2 – točka mjerenja 14 dana nakon 1. doze; T3 – točka mjerenja 7 dana nakon 2. doze; T4 – točka mjerenja 14 dana nakon 2. doze. Za laboratorijsku analizu je korištena elektrokemiluminiscentna imunokemijska metoda (ECLIA) temeljena na sendvič principu. Statistički značajna razlika između određivanih koncentracija kod svh ispitanika procijenjena je Wilcoxon signed-rank testom, dok je statistički značajna razlika između određivanja kod ispitanika bez hipertenzije i s hipertenzijom ispitana Mann-Whitneyevim testom. Moguća povezanost čimbenika s dobi te indeksom tjelesne mase ispitana je Spearmanovom korelacijom. Detaljnom analizom, unatoč određenim statistički značajnim razlikama, nisu pronađene klinički značajne promjene u koncentracijama PlGF i sFlt-1 uvjetovane cijepljenjem, niti je utvrđena razlika u koncentracijama između podskupina ispitanika bez hipertenzije i s hipertenzijom. Također, nije utvrđena značajna povezanost koncentracija PlGF i sFlt-1 u pojedinim točkama nakon cijepljenja s dobi, niti s indeksom tjelesne mase. S obzirom na dobivene rezultate, nije dokazano da pretpostavljeni mehanizam ima ulogu u nastanku tromboembolijskih incidenata nakon cijepljenja mRNA BNT162b cjepivom.
Abstract (english)	The incidence of thromboembolic events after SARS-CoV-2 vaccination is still one of the biggest concerns of the Covid-19 pandemic. Since vaccination imitates natural infection, we hypothesized that the dysregulation of the renin-angiotensin system, caused by spike protein binding, could induce an angiogenic imbalance leading to a hypercoagulable state and thromboembolic events. Based on this hypothesis, we tested dynamics in angiogenic factor concentration changes caused by the mRNA BNT162b vaccine. The specific aims of this study were to test the effect of vaccination on PlGF and sFlt-1 concentrations, the concentration difference between subgroups without and with hypertension, and to examine the correlation between PlGF and sFlt-1 with age and body mass index at defined time points after vaccination. The study included 33 adult subjects who were vaccinated with the mRNA BNT162b vaccine. Factors' concentrations were measured at five time points: T0 – measurement point before the1st dose (within 24h); T1 – measurement point 7 days after the 1st dose; T2 – measurement point 14 days after the 1st dose; T3 – measurement point 7 days after the 2nd dose; T4 – measurement point 14 days after the 2nd dose. Factors were measured using electrochemiluminescence method (ECLIA) based on the sandwich principle. The statistically significant difference between the measurements for all subjects was tested using Wilcoxon signed-rank test, while the statistically significant difference between subjects without and with hypertension was tested by using Mann-Whitney test. The possible correlation was tested by Spearman's correlation. Although statistically significant differences were obtained, they are indicated to be clinically irrelevant. No clinically significant changes in PlGF and sFlt-1 concentrations were found after vaccination. There were no differences in concentrations between subjects without hypertension and those with hypertension. No correlation was found between PlGF and sFlt-1 concentrations with age or body mass index at any time point after vaccination. According to the results, it has not been proven that the assumed mechanism participates in the incidence of thromboembolic incidents after vaccination with the mRNA BNT162b vaccine.
Keywords
Keywords (english)
Language	croatian
URN:NBN	urn:nbn:hr:163:579138
Study programme	Title: Medical biochemistry Study programme type: university Study level: integrated undergraduate and graduate Academic / professional title: magistar/magistra medicinske biokemije (magistar/magistra medicinske biokemije)
Type of resource	Text
File origin	Born digital
Access conditions	Embargoed access Embargo expiration date: 2025-06-27
Terms of use
Repository	Repository of Faculty of Pharmacy and Biochemistry University of Zagreb
Created on	2023-12-07 13:22:10